Preclinical verification of the efficacy and safety of aqueous plasma for ovarian cancer therapy

33Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The major cause of EOC’s lethality is that intraperitoneal recurrence occurs with high frequency due to occult metastasis. We had demonstrated that plasma-activated medium (PAM) exerts a metastasis-inhibitory effect on ovarian cancer in vitro and in vivo. Here we investigated how PAM inhibits intraperitoneal metastasis. We studied PAM’s inhibition of micro-dissemination onto the omentum by performing in vivo imaging in combination with a sequential histological analysis. The results revealed that PAM induced macrophage infiltration into the disseminated lesion. The iNOS-positive signal was co-localized at the macrophages in the existing lesion, indicating that PAM might induce M1-type macrophages. This may be another mechanism of the antitumor effect through a PAM-evoked immune response. Intraperitoneal lavage with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Our results demonstrated the efficiency and practicality of aqueous plasma for clinical applications.

Cite

CITATION STYLE

APA

Nakamura, K., Yoshikawa, N., Mizuno, Y., Ito, M., Tanaka, H., Mizuno, M., … Kajiyama, H. (2021). Preclinical verification of the efficacy and safety of aqueous plasma for ovarian cancer therapy. Cancers, 13(5), 1–15. https://doi.org/10.3390/cancers13051141

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free